Paule V Joseph1, Alissa Nolden2, Kord M Kober3, Steven M Paul3, Bruce A Cooper3, Yvette P Conley4, Marilyn J Hammer5, Fay Wright6, Jon D Levine7, Christine Miaskowski8. 1. Sensory Science & Metabolism Unit, Biobehavioral Branch, Division of Intramural Research, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA. 2. Department of Food Science, College of Natural Sciences, University of Massachusetts, Amherst, Massachusetts, USA. 3. Department of Physiological Nursing, School of Nursing, University of California, San Francisco, California, USA. 4. School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 5. Dana Farber Cancer Institute, Boston, Massachusetts, USA. 6. Rory Meyers College of Nursing, New York University, New York, New York, USA. 7. Department of Medicine, School of Medicine, University of California, San Francisco, California, USA. 8. Department of Physiological Nursing, School of Nursing, University of California, San Francisco, California, USA; Department of Medicine, School of Medicine, University of California, San Francisco, California, USA. Electronic address: chris.miaskowski@ucsf.edu.
Abstract
CONTEXT: A common complaint among oncology patients receiving chemotherapy is altered taste perception. OBJECTIVE: The purpose of this study was to evaluate for differences in common symptoms and stress levels in patients who reported taste changes. METHODS: Patients were receiving chemotherapy for breast, gastrointestinal, gynecological, or lung cancer. Change in the way food tastes (CFT) was assessed using the Memorial Symptom Assessment Scale before the patients' second or third cycle of chemotherapy. Valid and reliable instruments were used to assess for depressive symptoms, state and trait of anxiety, cognitive impairment, diurnal variations in fatigue and energy, sleep disturbance, and pain. Stress was assessed using the Perceived Stress Scale and the Impact of Events Scale-Revised. Multiple logistic regression was used to evaluate for risk factors associated with CFT. RESULTS: Of the 1329 patients, 49.4% reported CFT. Patients in the CFT group reported higher levels of depression, anxiety, fatigue, and sleep disturbance as well as higher levels of general and disease specific stress. Factors associated with CFT group included being non-White; receiving an antiemetic regimen that contained a neurokinin-1 receptor antagonist with two other antiemetics; having a lower functional status; higher levels of morning fatigue; and reporting higher scores on the hyperarousal subscale of the Impact of Event Scale-Revised. CONCLUSIONS: This study provides new evidence on associations between taste changes and common co-occurring symptoms and stress in oncology patients receiving chemotherapy. Clinicians need to evaluate for taste changes in these patients because this symptom can effect patients' nutritional intake and quality of life.
CONTEXT: A common complaint among oncology patients receiving chemotherapy is altered taste perception. OBJECTIVE: The purpose of this study was to evaluate for differences in common symptoms and stress levels in patients who reported taste changes. METHODS: Patients were receiving chemotherapy for breast, gastrointestinal, gynecological, or lung cancer. Change in the way food tastes (CFT) was assessed using the Memorial Symptom Assessment Scale before the patients' second or third cycle of chemotherapy. Valid and reliable instruments were used to assess for depressive symptoms, state and trait of anxiety, cognitive impairment, diurnal variations in fatigue and energy, sleep disturbance, and pain. Stress was assessed using the Perceived Stress Scale and the Impact of Events Scale-Revised. Multiple logistic regression was used to evaluate for risk factors associated with CFT. RESULTS: Of the 1329 patients, 49.4% reported CFT. Patients in the CFT group reported higher levels of depression, anxiety, fatigue, and sleep disturbance as well as higher levels of general and disease specific stress. Factors associated with CFT group included being non-White; receiving an antiemetic regimen that contained a neurokinin-1 receptor antagonist with two other antiemetics; having a lower functional status; higher levels of morning fatigue; and reporting higher scores on the hyperarousal subscale of the Impact of Event Scale-Revised. CONCLUSIONS: This study provides new evidence on associations between taste changes and common co-occurring symptoms and stress in oncology patients receiving chemotherapy. Clinicians need to evaluate for taste changes in these patients because this symptom can effect patients' nutritional intake and quality of life.
Authors: F Roila; A Molassiotis; J Herrstedt; M Aapro; R J Gralla; E Bruera; R A Clark-Snow; L L Dupuis; L H Einhorn; P Feyer; P J Hesketh; K Jordan; I Olver; B L Rapoport; J Roscoe; C H Ruhlmann; D Walsh; D Warr; M van der Wetering Journal: Ann Oncol Date: 2016-09 Impact factor: 32.976
Authors: Gabriela Barbaglia; Margreet ten Have; Saskia van Dorsselaer; Jordi Alonso; Gemma Vilagut; Ron de Graaf Journal: Qual Life Res Date: 2014-09-18 Impact factor: 4.147
Authors: E Ponticelli; M Clari; S Frigerio; A De Clemente; I Bergese; E Scavino; A Bernardini; C Sacerdote Journal: Eur J Cancer Care (Engl) Date: 2017-01-19 Impact factor: 2.520
Authors: Dale J Langford; Bruce Cooper; Steven Paul; Janice Humphreys; Marilyn J Hammer; Jon Levine; Yvette P Conley; Fay Wright; Laura B Dunn; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-11-09 Impact factor: 3.612
Authors: Katarina Jakovljevic; Kord M Kober; Astrid Block; Bruce A Cooper; Steven M Paul; Marilyn J Hammer; Frances Cartwright; Yvette P Conley; Fay Wright; Laura B Dunn; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2020-07-25 Impact factor: 3.612
Authors: Yfke C de Vries; Esther Helmich; Matty D A Karsten; Sanne Boesveldt; Renate M Winkels; Hanneke W M van Laarhoven Journal: Support Care Cancer Date: 2016-02-27 Impact factor: 3.603
Authors: Ana Sofia Spencer; David da Silva Dias; Manuel Luís Capelas; Francisco Pimentel; Teresa Santos; Pedro Miguel Neves; Antti Mäkitie; Paula Ravasco Journal: Front Oncol Date: 2021-11-22 Impact factor: 6.244